Search

Your search keyword '"Yang, Guangli"' showing total 48 results

Search Constraints

Start Over You searched for: Author "Yang, Guangli" Remove constraint Author: "Yang, Guangli" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
48 results on '"Yang, Guangli"'

Search Results

1. Supplementary Methods and Figures S1 to S7 from CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment

2. Data from CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment

3. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

4. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

5. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

6. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

7. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

8. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

9. Data from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

10. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

11. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

12. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

13. Data from CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment

14. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

15. Data from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

16. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

17. Supplementary Methods and Figures S1 to S7 from CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment

18. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

19. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

20. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

21. Supplementary Table 4 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

22. Supplementary Table 2 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

23. Supplementary figure S4 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

24. Supplementary Table 1 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

25. Supplementary Methods and Figure Legends from Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

26. Supplementary Figure S3 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

27. Supplementary Table 3 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

28. Supplementary Table 1 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

29. Supplementary Table 3 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

30. Supplementary Figure S2 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

31. Supplementary Table 2 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

32. Supplementary Figure S1 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

33. Supplementary Figure S2 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

34. Supplementary Figures 1-3 from Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

35. Supplementary Figure S3 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

36. Supplementary Methods and Figure Legends from Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

37. Supplementary Table 4 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

38. Supplementary figure S4 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

39. Supplementary Figures 1-3 from Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

40. Supplementary Figure S5 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

41. Supplementary Figure S5 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

42. Supplementary Figure S1 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

43. Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125 Selective Agents

44. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment

45. Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

46. Abstract 4975: A small molecule pan Id protein antagonist shows strong antitumor activity

47. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

Catalog

Books, media, physical & digital resources